Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Vincenzo Montesarchio; Roberto Parrella; Chiara Iommelli; Antonella Bianco; Elio Manzillo; Fiorentino Fraganza; Cristiana Palumbo; Gaetano Rea; Patrizia Murino; Rosanna De Rosa; Luigi Atripaldi; Maurizio D’Abbraccio; Marcello Curvietto; Domenico Mallardo; Egidio Celentano; Antonio Maria Grimaldi; Marco Palla; Claudia Trojaniello; Maria Grazia Vitale; Samuel Lewis Million-Weaver; Paolo Antonio Ascierto

doi:10.1136/jitc-2020-001089

Citation Tools

This article has a correction. Please see:

Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy - September 01, 2020

PDF

XML

Case report

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Montesarchio V, Parrella R, Iommelli C, et al

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Journal for ImmunoTherapy of Cancer 2020;8:e001089. doi: 10.1136/jitc-2020-001089

Log in using your username and password

Main menu

Log in using your username and password

You are here

This article has a correction. Please see:

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password